Trial reportAddictive behaviors2012
Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.
Trial report in Addictive behaviors, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01751386 (A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2019Pooled it
- Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016Pooled it
- Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.Addiction science & clinical practice · 2015Pooled it
- A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.Psychopharmacology · 2015Trial
- Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.Alcohol and alcoholism (Oxford, Oxfordshire) · 2014Trial
- A human laboratory pilot study with baclofen in alcoholic individuals.Pharmacology, biochemistry, and behavior · 2013Trial
- Integrated Multidisciplinary Management of Alcohol-associated Liver Disease.Journal of clinical and translational hepatology · 2023Review
- Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis.BMC gastroenterology · 2023Article
- Therapeutic Pipeline in Alcohol-Associated Liver Disease.Seminars in liver disease · 2023Review
- Receipt of evidence-based alcohol-related care in a national sample of transgender patients with unhealthy alcohol use: Overall and relative to non-transgender patients.Journal of substance abuse treatment · 2021Article
- Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities.Transplantation direct · 2020Article
- Inter-professional and inter-departmental alcoholism rehabilitation program.Clinical and molecular hepatology · 2020Article
- Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.Hepatology (Baltimore, Md.) · 2020Article
- New Treatment Models for Alcohol Use Disorders and Alcoholic Liver Disease.Clinical liver disease · 2019Review
- An Overview of Pharmacotherapy Options for Alcohol Use Disorder.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018Article
- Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.Drug and alcohol dependence · 2018Article
- Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence.Frontiers in psychiatry · 2018Review
- Pathophysiology and Management of Alcoholic Liver Disease: Update 2016.Gut and liver · 2017Review
- Management of alcohol misuse in patients with liver diseases.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Hepatitis C virus (HCV) and alcoholic liver disease (ALD), either alone or in combination, count for more than two thirds of all liver diseases in the Western world. There is no safe level of drinking in HCV-infected patients and the most effective goal for these patients is total abstinence. Baclofen, a GABA(B) receptor agonist, represents a promising pharmacotherapy for alcohol dependence (AD). Previously, we performed a randomized clinical trial (RCT), which demonstrated the safety and efficacy of baclofen in patients affected by AD and cirrhosis. The goal of this post-hoc analysis was to explore baclofen's effect in a subgroup of alcohol-dependent HCV-infected cirrhotic patients. Any patient with HCV infection was selected for this analysis. Among the 84 subjects randomized in the main trial, 24 alcohol-dependent cirrhotic patients had a HCV infection; 12 received baclofen 10mg t.i.d. and 12 received placebo for 12-weeks. With respect to the placebo group (3/12, 25.0%), a significantly higher number of patients who achieved and maintained total alcohol abstinence was found in the baclofen group (10/12, 83.3%; p=0.0123). Furthermore, in the baclofen group, compared to placebo, there was a significantly higher increase in albumin values from baseline (p=0.0132) and a trend toward a significant reduction in INR levels from baseline (p=0.0716). In conclusion, baclofen was safe and significantly more effective than placebo in promoting alcohol abstinence, and improving some Liver Function Tests (LFTs) (i.e. albumin, INR) in alcohol-dependent HCV-infected cirrhotic patients. Baclofen may represent a clinically relevant alcohol pharmacotherapy for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.